Arizona Biosciences News

TGen launches global pancreatic cancer research program

Summary:

The Translational Genomics Research Institute has announced plans to launch an international pancreatic cancer research program. The Pancreatic Cancer Research Team, or PCRT, will strive toward better treatment and the eventual eradication of the lethal disease.

Full Story:

The Translational Genomics Research Institute has announced plans to launch an international pancreatic cancer research program. The Pancreatic Cancer Research Team, or PCRT, will strive toward better treatment and the eventual eradication of the lethal disease.

According to the Business Journal, scientists will conduct genomic analysis of pancreatic cancer cells to rapidly identify abnormalities in tumors and convert this knowledge into therapies. They will also cooperatively study drugs developed for other cancers to determine if they are effective against pancreatic cancer.

Pancreatic cancer is difficult to detect and has a low survival rate. There are currently only two drugs approved by the U.S. Food and Drug Administration for the disease.

A key advantage of the international approach is that it offers the opportunity to conduct clinical trials with giant pools of patient participants. This will prove important in the PCRT's efforts to speed the process of bringing drugs to market. This process currently takes an average of 14 years.


For more information:

"TGen kicks off pancreatic cancer program to conduct global trials," The Business Journal, 12/08/2003